APPLICATIONS
Drug Delivery
Drug formulators are using self-absorbable polymers to create drug delivery systems that improve the patient’s health. Flexibility, convenience and better compliance to meet patient needs can all be incorporated into the system design process involving the use of Proteins, vaccines, and other biological molecules. Scientists can use our polymer to develop & manufacture strategies of controlled release injectable depots, micro/nanoparticles, and solid implants. API together with polymer and solvent is mixed to form a gel which is injected into the patient so that the drug can release as per necessity.
Medical Devices
Bioresorbable Polymers are valuable additives inside the design and manufacture of Medical Devices such as: Screws, Plates and Bone regeneration scaffolds, Staples and Sutures, Neural conduits, Hernia meshes, Stents, Device coatings, Dental and Ophthalmic treatments
- Poly(L-Lactide) (PLLA)
- Poly(ɛ-Caprolactone) (PCL)
- Poly(L-Lactide-co-ɛ-Caprolactone) (PLCL)
- Poly(Glycolide) (PGA)
Poly (DL-Lactide-co-Glycolide) PLGA
CAS Number: 26780-50-7
The ratio of Lactide and Glycolide: PLGA5050/">PLGA 50:50, PLGA 75:25, PLGA 85:15, PLGA 55:45, PLGA 45:55, PLGA 55:45 Star Glucose, PLGA 90:10, PLGA 10:90, Or any custom ratio of La and GA.
Inherent viscosity (IV.) range: 0.15 dg/L to 2.3 dg/L
End Group: Acid terminated, Ester terminated, Hydroxy terminated, etc.
Poly (D, L-Lactide) (PDLLA)
Synonym: Polylactic acid, Poly(L-lactide), Poly(D,L-lactide) , Poly(D-lactide), PLA, PLLA, PDLA, PDA, PDLLA etc.
CAS Number: 33135-50-1
The ratio of L-Lactide and D-Lactide: PLLA 100: 00, PDLLA 50:50, PDLLA 75:25 ,PDLLA25:75 , PDLA 00:100 etc.
Inherent viscosity (IV.) range: 0.15 dg/L to 2.3 dg/L
End Group: Acid terminated, Ester terminated, Hydroxy terminated, etc.
Other Polymers
All bioresorbable polymers can be customized with defined chemical structures/composition, molar mass (molecular weight or inherent viscosity) & selective terminal end groups. some are as Poly(D, L-Lactide-co-Glycolide-co-PEG) (PLGA-PEG-PLGA), Poly(ɛ-Caprolactone) (PCL), Poly(L-Lactide-co-ɛ-Caprolactone) (PLCL), Poly(Glycolide) (PGA), PLGA-NH2, M-PEG-OH, M-PEG-PLGA, M-PEG-NH2.
Recent Posts for PLGA Applications
mPEG-PLA Polymer: A Key Component in Nanoparticle Drug Delivery
The landscape of drug delivery systems has evolved significantly in recent years, with nanotechnology playing a pivotal role. One of the noteworthy innovations in this space is Cynviloq, a nanoparticle formulation of the chemotherapeutic agent paclitaxel. At the core...
Introduces Sterile PLGA 50:50 for Treptorelin Depot Formulation
Bioresorbable solid implants for peptides : Goserelin acetate
PLGA microspheres
Zoladex (Goserelin acetate) and Lupron Depot (Leuprolide acetate) for the treatment of prostate cancer and breast cancer. The use of PLGA and PLA-based delivery systems have made it possible to create extended-release formulations, that can lower the frequency of dosing and lesser side effects from medications
PLGA, a smart polymer for Drug Delivery System
The technology to deliver the necessary ingredients to the target area and sustain the efficacy there for a long time is the medical technology called DDS(Drug Delivery System). Polylactic-co-glycolic acid (PLGA) or PLG is a copolymer of polylactic acid (PLA) and...